pipette
ESEspañol

Real-world effectiveness of nirsevimab over three RSV seasons in an integrated health care system: a target trial emulation study

S. S. Kim, E. Wu, A. F. Hudgins, M. Crawford, M. Bruck, F. Lobelo, D. Benkeser, E. T. Rogawski McQuade

PreprintReal-world use

In the authors' words

Most nirsevimab effectiveness estimates come from test-negative designs, which restrict populations to those seeking healthcare and testing. We estimated nirsevimab effectiveness among infants six months post-receipt using a target trial emulation with an estimand aligned to phase 3 trials. We emulated a target trial among infants born from February 2, 2023 through May 30, 2026, using electronic medical records at Kaiser Permanente Georgia. Using a g-computation estimator with Cox models fit separately in nirsevimab recipients and non-recipients, we estimated the cumulative incidence of RSV hospitalization and medically-attended RSV at 30-day intervals through 180 days post-receipt. Among 4,826 infants, nirsevimab reduced the risk of RSV hospitalization by 95% (95% CI: 84% to 98%) and medically-attended RSV by 67% (95% CI: 45% to 80%) at 180 days post-receipt. The number needed to immunize to prevent one case was 147 (95% CI: 94 to 333) for RSV hospitalization and 39 (95% CI: 28 to 68) for medically-attended RSV. Nirsevimab was effective through 180 days post-receipt. This cohort-based emulation avoids conditioning on testing and the restricted generalizability of the test-negative and matching-based designs that dominate the literature. These findings support continued nirsevimab use to protect infants against RSV.

Main resultThe abstract does not state a limitation.

Appeared: Monday, November 16. medRxiv. Preprint, not yet peer-reviewed.

DOI: 10.64898/2026.11.12.26367940